Methods and compositions for treating proliferative diseases
The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
1. A pharmaceutical composition comprising nanoparticles comprising 17-AAG and an albumin, wherein the nanoparticles comprise 17-AAG coated with the albumin, wherein the average diameter of the nanoparticles in the composition is no greater than about 500 nm.
2. The pharmaceutical composition according to claim 1 , wherein the albumin is human serum albumin.
3. The pharmaceutical composition according to claim 2 , wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm.
4. The pharmaceutical composition according to claim 1 , wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm.
5. The pharmaceutical composition according to claim 4 , wherein the average diameter of the nanoparticles in the composition is no greater than about 100 nm.
6. The pharmaceutical composition according to claim 1 , wherein the weight ratio of the albumin to 17-AAG in the composition is less than about 18:1.
7. The pharmaceutical composition according to claim 6 , wherein the weight ratio of the albumin to 17-AAG in the composition is about 2:1 to about 15:1.
8. The pharmaceutical composition according to claim 7 , wherein the weight ratio of the albumin to 17-AAG in the composition is about 3:1 to about 12:1.
9. The pharmaceutical composition according to claim 8 , wherein the weight ratio of the albumin to 17-AAG in the composition is about 4:1 to about 10:1.
10. The pharmaceutical composition according to claim 1 , wherein the composition does not induce significant side effects.